Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MNKD
stocks logo

MNKD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
100.96M
+31.5%
0.019
-53.13%
107.80M
+37.58%
0.021
-29.17%
112.15M
+46.55%
-0.010
-125%
Estimates Revision
The market is revising Upward the revenue expectations for MannKind Corporation (MNKD) for FY2025, with the revenue forecasts being adjusted by 8.9% over the past three months. During the same period, the stock price has changed by 6.64%.
Revenue Estimates for FY2025
Revise Upward
up Image
+8.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.51%
In Past 3 Month
Stock Price
Go Up
up Image
+6.64%
In Past 3 Month
Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.50 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.50 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.940
sliders
Low
7.50
Averages
9.25
High
11.00
Current: 5.940
sliders
Low
7.50
Averages
9.25
High
11.00
Truist
initiated
$9
2025-11-24
Reason
Truist
Price Target
$9
2025-11-24
initiated
Reason
Truist initiated coverage of MannKind with a Buy rating and $9 price target. MannKind continues to execute with their technology, with both Afrezza and Tyvaso DPI, and the recent acquisition of scPharmaceuticals adds another topline driver, Furoscix, for fluid overload, the analyst tells investors in a research note. MannKind's orphan lung pipeline continues to advance for longer-term diversification and growth for the company, Truist says.
Oppenheimer
Oppenheimer
Outperform
to
NULL
downgrade
$15 -> $10
2025-11-11
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $10
2025-11-11
downgrade
Outperform
to
NULL
Reason
Oppenheimer lowered the firm's price target on MannKind to $10 from $15 and keeps an Outperform rating on the shares after removing MNKD-101/NTM from its pipeline valuation. The firm cites discontinuation of the Phase 3 ICoN-1 trial for nontuberculosis mycobacterial lung disease after a review by the Data Safety Monitoring Board determined that proceeding with the study would be futile as no sputum culture conversions were observed.
Oppenheimer
Oppenheimer
Outperform
maintain
$12 -> $15
2025-09-05
Reason
Oppenheimer
Oppenheimer
Price Target
$12 -> $15
2025-09-05
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on MannKind to $15 from $12 and keeps an Outperform rating on the shares. The firm is updating its model to include TYVASO DPI royalties following positive Phase 3 results from TETON-2 in IPF and FUROSCIX following the acquisition of scPharma. Oppenheimer sees TYVASO becoming a backbone therapy in IPF generating about $5.4B in sales in 2033 and subsequently enhancing MannKind's DPI royalty stream.
RBC Capital
Douglas Miehm
Outperform
maintain
$7 -> $8
2025-08-26
Reason
RBC Capital
Douglas Miehm
Price Target
$7 -> $8
2025-08-26
maintain
Outperform
Reason
RBC Capital analyst Douglas Miehm raised the firm's price target on MannKind (MNKD) to $8 from $7 and keeps an Outperform rating on the shares. The firm views the company's announced acquisition of scPharmaceuticals (SCPH) positively as it adds a high-growth commercial asset with a large total addressable market of about $13B, diversifies MannKind revenue base, and the acquisition multiple is "attractive", the analyst tells investors in a research note.
H.C. Wainwright
Brandon Folkes
Buy
maintain
$9
2025-08-06
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$9
2025-08-06
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes views the selloff in shares of MannKind post the Q2 report as overdone. The market "continues to miss" the drivers of MannKind's future, which include Afrezza pediatric uptake and the pipeline of MNKD-101 and MNKD-201, the analyst tells investors in a research note. The firm believes the Q2 updates on MannKind's future value drivers were largely positive. H.C. Wainwright believes the stock remains undervalued fundamentally. It keeps a Buy rating on MannKind with a $9 price target.
RBC Capital
Outperform
downgrade
$10 -> $8
2025-07-23
Reason
RBC Capital
Price Target
$10 -> $8
2025-07-23
downgrade
Outperform
Reason
RBC Capital lowered the firm's price target on MannKind to $8 from $10 and keeps an Outperform rating on the shares following a transfer of coverage. The stock price reflects an overly pessimistic view of MannKind's commercial products, especially the Tyvaso DPI royalties, and assigns no value to the pipeline, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for MannKind Corp (MNKD.O) is 86.51, compared to its 5-year average forward P/E of 16.83. For a more detailed relative valuation and DCF analysis to assess MannKind Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
16.83
Current PE
86.51
Overvalued PE
79.65
Undervalued PE
-45.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.40
Undervalued EV/EBITDA
-38.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
7.29
Current PS
3.94
Overvalued PS
10.85
Undervalued PS
3.73
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1407.97% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 337.78% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1407.97% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

MNKD News & Events

Events Timeline

(ET)
2025-12-01
08:10:00
MannKind Seeks FDA Approval for FUROSCIX ReadyFlow Autoinjector
select
2025-11-10 (ET)
2025-11-10
11:03:22
H.C. Wainwright maintains positive outlook on MannKind despite letdown from MNKD-101 update.
select
2025-11-10
08:21:13
MannKind Offers Update on Phase 3 ICoN-1 Trial for Nebulized Clofazimine
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02NASDAQ.COM
MannKind's FUROSCIX ReadyFlow Autoinjector Submitted for FDA Review; PDUFA Date Scheduled for July

  • FDA Review Acceptance: MannKind Corp.'s supplemental new drug application for the FUROSCIX ReadyFlow Autoinjector, aimed at treating edema in adults with chronic heart failure or chronic kidney disease, has been accepted by the FDA, with a decision expected by July 26, 2026.

  • Advantages of ReadyFlow Autoinjector: The ReadyFlow Autoinjector is designed to deliver a dose of furosemide in under 10 seconds, potentially reducing hospital admissions and overall healthcare costs compared to the current On-Body Infusor, which takes about 5 hours.

  • Positive Study Results: The sNDA submission is backed by positive trial results showing that the ReadyFlow Autoinjector meets FDA bioavailability requirements and provides comparable therapeutic outcomes to intravenous furosemide, with minimal side effects.

  • Market Performance: MannKind's stock closed at $5.43, reflecting a 1.50% increase, with trading volume significantly higher than average, indicating strong investor interest over the past year.

[object Object]
Preview
9.0
12-01Globenewswire
MannKind Seeks FDA Approval for ReadyFlow Autoinjector to Deliver Diuretic in Under 10 Seconds
  • Innovative Delivery Method: MannKind's ReadyFlow Autoinjector can deliver an 80 mg/ml furosemide injection in under 10 seconds, significantly reducing administration time from five hours, which is expected to enhance treatment experiences for patients with chronic heart failure and chronic kidney disease.
  • Increased Patient Convenience: If approved, ReadyFlow will enable patients to manage fluid buildup episodes conveniently at home, potentially reducing hospital admissions and alleviating the burden on the healthcare system while lowering overall healthcare costs.
  • FDA Review Progress: The application has been accepted by the FDA with a target action date of July 26, 2026, marking a significant milestone in MannKind's drug development efforts that could positively influence the company's future market performance.
  • Clinical Study Support: The studies supporting this application demonstrated a bioavailability of 107.3% for ReadyFlow, with similar urine output compared to IV furosemide, indicating its effectiveness and tolerability in clinical applications, thereby enhancing market confidence.
[object Object]
Preview
9.0
12-01Newsfilter
MannKind Seeks FDA Approval for ReadyFlow Autoinjector to Deliver Furosemide in Under 10 Seconds
  • Rapid Administration Innovation: MannKind's ReadyFlow Autoinjector can deliver an 80 mg/ml furosemide injection in under 10 seconds, significantly reducing administration time from five hours to under 10 seconds, thereby enhancing treatment efficiency for patients with chronic heart failure and chronic kidney disease.
  • Increased Patient Convenience: If approved, ReadyFlow would enable patients to manage fluid buildup episodes at home, reducing hospital admissions and alleviating overall healthcare costs, thus improving patients' quality of life.
  • FDA Review Process: The application has a PDUFA target action date of July 26, 2026, marking a significant milestone for MannKind in chronic disease treatment, which could transform patient care.
  • Clinical Study Support: The application is backed by studies showing a bioavailability of 107.3% for the ReadyFlow injector, with similar urine output compared to IV furosemide, indicating its effectiveness and safety in clinical use.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MannKind Corp (MNKD) stock price today?

The current price of MNKD is 5.94 USD — it has increased 2.24 % in the last trading day.

arrow icon

What is MannKind Corp (MNKD)'s business?

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

arrow icon

What is the price predicton of MNKD Stock?

Wall Street analysts forecast MNKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNKD is 9.25 USD with a low forecast of 7.50 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MannKind Corp (MNKD)'s revenue for the last quarter?

MannKind Corp revenue for the last quarter amounts to 82.13M USD, increased 17.20 % YoY.

arrow icon

What is MannKind Corp (MNKD)'s earnings per share (EPS) for the last quarter?

MannKind Corp. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for MannKind Corp (MNKD)'s fundamentals?

The market is revising Upward the revenue expectations for MannKind Corporation (MNKD) for FY2025, with the revenue forecasts being adjusted by 8.9% over the past three months. During the same period, the stock price has changed by 6.64%.
arrow icon

How many employees does MannKind Corp (MNKD). have?

MannKind Corp (MNKD) has 407 emplpoyees as of December 13 2025.

arrow icon

What is MannKind Corp (MNKD) market cap?

Today MNKD has the market capitalization of 1.82B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free